Preoperative Enoxaparin Versus Postoperative Semuloparin Thromboprophylaxis in Major Abdominal Surgery A Randomized Controlled Trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F14%3A10294025" target="_blank" >RIV/00216208:11130/14:10294025 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61383082:_____/14:#0000285

Výsledek na webu

<a href="http://dx.doi.org/10.1097/SLA.0000000000000430" target="_blank" >http://dx.doi.org/10.1097/SLA.0000000000000430</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/SLA.0000000000000430" target="_blank" >10.1097/SLA.0000000000000430</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Preoperative Enoxaparin Versus Postoperative Semuloparin Thromboprophylaxis in Major Abdominal Surgery A Randomized Controlled Trial

Popis výsledku v původním jazyce

Objective: To compare efficacy and safety of thromboprophylaxis with semuloparin started postoperatively versus enoxaparin started preoperatively in major abdominal surgery. Background: Venous thromboembolism is an important complication following majorabdominal surgery. Semuloparin is a novel ultra-low-molecular-weight heparin with high antifactor Xa and minimal antifactor IIa activity. Methods: In this double-blind noninferiority trial, adult patients undergoing major abdominal or pelvic operation under general anesthesia lasting more than 45 minutes were assigned to either daily enoxaparin 40 mg commenced preoperatively or daily semuloparin 20 mg commenced postoperatively, for 7 to 10 days. Patients underwent bilateral leg venography between 7 and11 days postsurgery. The primary efficacy end point was the composite of any deep vein thrombosis, nonfatal pulmonary embolism, or all-cause death. The primary safety outcome was bleeding. Both were independently adjudicated. Results: In

Název v anglickém jazyce

Preoperative Enoxaparin Versus Postoperative Semuloparin Thromboprophylaxis in Major Abdominal Surgery A Randomized Controlled Trial

Popis výsledku anglicky

Objective: To compare efficacy and safety of thromboprophylaxis with semuloparin started postoperatively versus enoxaparin started preoperatively in major abdominal surgery. Background: Venous thromboembolism is an important complication following majorabdominal surgery. Semuloparin is a novel ultra-low-molecular-weight heparin with high antifactor Xa and minimal antifactor IIa activity. Methods: In this double-blind noninferiority trial, adult patients undergoing major abdominal or pelvic operation under general anesthesia lasting more than 45 minutes were assigned to either daily enoxaparin 40 mg commenced preoperatively or daily semuloparin 20 mg commenced postoperatively, for 7 to 10 days. Patients underwent bilateral leg venography between 7 and11 days postsurgery. The primary efficacy end point was the composite of any deep vein thrombosis, nonfatal pulmonary embolism, or all-cause death. The primary safety outcome was bleeding. Both were independently adjudicated. Results: In

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FI - Traumatologie a ortopedie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Annals of Surgery

ISSN

0003-4932

e-ISSN

—

Svazek periodika

6

Číslo periodika v rámci svazku

259

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

1073-1079

Kód UT WoS článku

000337296700016

EID výsledku v databázi Scopus

—